MANNKIND CORP Income (Loss) from Continuing Operations before Income Taxes, Domestic
MANNKIND CORP (MNKD) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $1.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- MANNKIND CORP income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $1.41M, a 95.39% decline from fiscal 2024.
- MANNKIND CORP income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $30.52M.
- MANNKIND CORP income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$10.38M.
- MANNKIND CORP income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$87.40M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $1.41M 10-K · filed 2026-02-26 |
| 2024-12-31 | $30.52M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$10.38M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$87.40M 10-K · filed 2025-02-26 |
| 2021-12-31 | -$80.93M 10-K · filed 2024-02-27 |
| 2020-12-31 | -$57.46M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$51.04M 10-K · filed 2021-02-25 |
| 2018-12-31 | -$84.21M 10-K · filed 2020-02-25 |
| 2017-12-31 | -$113.68M 10-K · filed 2019-02-26 |
| 2016-12-31 | $129.36M 10-K · filed 2019-02-26 |
| 2015-12-31 | -$358.05M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |